[go: up one dir, main page]

AR131602A1 - Uso del compuesto 1 en el tratamiento o prevención de la fibrosis renal y otras enfermedades - Google Patents

Uso del compuesto 1 en el tratamiento o prevención de la fibrosis renal y otras enfermedades

Info

Publication number
AR131602A1
AR131602A1 ARP240100073A ARP240100073A AR131602A1 AR 131602 A1 AR131602 A1 AR 131602A1 AR P240100073 A ARP240100073 A AR P240100073A AR P240100073 A ARP240100073 A AR P240100073A AR 131602 A1 AR131602 A1 AR 131602A1
Authority
AR
Argentina
Prior art keywords
diseases
prevention
compound
treatment
renal fibrosis
Prior art date
Application number
ARP240100073A
Other languages
English (en)
Inventor
Xun He
Feng Jin
Yuhan Guo
Tianyuan Zhang
Zhenwei Li
Baoru Lv
Wei Hu
Original Assignee
Shenzhen Newdel Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Newdel Biotech Co Ltd filed Critical Shenzhen Newdel Biotech Co Ltd
Publication of AR131602A1 publication Critical patent/AR131602A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de N-(3-cloro-5-(trifluorometil)fenil)-3-((6-(4-hidroxipiperidin-1-il)imidazo[1,2-b]piridazin-3-il)etinil)-2-metilbenzamida (también denominada en la presente compuesto 1) o una sal farmacéuticamente aceptable de este en el tratamiento o prevención de la fibrosis renal y otras enfermedades.
ARP240100073A 2023-01-13 2024-01-12 Uso del compuesto 1 en el tratamiento o prevención de la fibrosis renal y otras enfermedades AR131602A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310077067 2023-01-13

Publications (1)

Publication Number Publication Date
AR131602A1 true AR131602A1 (es) 2025-04-09

Family

ID=91897781

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP240100073A AR131602A1 (es) 2023-01-13 2024-01-12 Uso del compuesto 1 en el tratamiento o prevención de la fibrosis renal y otras enfermedades
ARP240100076A AR131603A1 (es) 2023-01-13 2024-01-12 Uso del compuesto 1 en el tratamiento o prevención de la fibrosis renal y otras enfermedades

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP240100076A AR131603A1 (es) 2023-01-13 2024-01-12 Uso del compuesto 1 en el tratamiento o prevención de la fibrosis renal y otras enfermedades

Country Status (7)

Country Link
EP (1) EP4646202A4 (es)
JP (1) JP2026503263A (es)
KR (1) KR20250129808A (es)
CN (1) CN120475970A (es)
AR (2) AR131602A1 (es)
TW (1) TW202434232A (es)
WO (1) WO2024149364A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230170938A (ko) * 2021-04-13 2023-12-19 선전 뉴델 바이오텍 씨오., 엘티디. 알키닐페닐벤즈아미드계 화합물 및 이의 응용

Also Published As

Publication number Publication date
JP2026503263A (ja) 2026-01-28
CN120475970A (zh) 2025-08-12
AR131603A1 (es) 2025-04-09
EP4646202A1 (en) 2025-11-12
EP4646202A4 (en) 2025-12-31
WO2024149364A1 (en) 2024-07-18
KR20250129808A (ko) 2025-08-29
TW202434232A (zh) 2024-09-01

Similar Documents

Publication Publication Date Title
GEAP202315648A (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
MX394415B (es) Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2).
UY26926A1 (es) Derivados de la quinolina y quinazolina
CL2009001250A1 (es) Sal del acido dihidroclorico y dibencensulfonico de 2-fluoro-n-metil-4-[7-(quinolin-6-ilmetil)imidazol[1,2-b][1,2,4]1,2,4]triazin-2-il]benzamida; compuestos intermediarios; procesos de preparacion; composicion farmaceutica; y uso para tratar cancer, aterosclerosis, fibrosis pulmonar, enfermedad renal, entre otras.
PH12020550452A1 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
CY1116215T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
TW200502230A (en) Dual nk1/nk3 derivatives
WO2008010953A3 (en) Pyridinone diketo acids: inhibitors of hiv replication in combination therapy
UY27462A1 (es) Derivados de quinolina
GEP20063751B (en) 2-Acyl Indol Derivatives and Their Use as Anti-Tumour Agents
ES2188604T3 (es) Inhibidores de proteasa del vih en combinaciones farmaceuticas para eltratamiento del sida.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
ES2694375T3 (es) Composiciones para el tratamiento de la hipertensión y/o de la fibrosis
ECSP22089498A (es) Inhibidores de il4i1 y métodos de uso
EA201270651A1 (ru) Карбоксамиды пиридинон гидроксициклопентила: ингибиторы вич интегразы и области терапевтического применения
PH12020551772A1 (en) Oxo-substituted compound
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
AR131602A1 (es) Uso del compuesto 1 en el tratamiento o prevención de la fibrosis renal y otras enfermedades
AR131604A1 (es) Uso del compuesto 1 en el tratamiento o la prevención de dermatitis atópica
GEP20063754B (en) Quinoline Derivatives and Use Thereof as Antitumor Agents
ATE378335T1 (de) Chirale fluorochinolizinon arginine salze
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
WO2006125178A3 (en) Tricyclic pyridazine compounds and their uses as therapeutic agents
AR133621A1 (es) USO DEL COMPUESTO 1 EN EL TRATAMIENTO O LA PREVENCIÓN DE UNA ENFERMEDAD ASOCIADA CON LA MUTACIÓN DE c-KIT O LA MUTACIÓN DE FUSIÓN DE c-KIT

Legal Events

Date Code Title Description
FB Suspension of granting procedure